Funding for this research was provided by:
National Heart, Lung, and Blood Institute (P01HL053749)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U01 AI142756)
National Human Genome Research Institute (RM1 HG009490)
National Institute of Biomedical Imaging and Bioengineering (R01 EB022376)
National Institute of General Medical Sciences (R35 GM118062)
Received: 13 November 2019
Revised: 2 February 2020
Accepted: 7 February 2020
First Online: 16 March 2020
Change Date: 20 May 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
: The authors declare competing financial interests. D.R.L. is a consultant and co-founder of Editas Medicine, Pairwise Plants, Beam Therapeutics, and Prime Medicine, companies that use genome editing. The authors have filed patent applications on evolved ABEs. The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, and Mammoth Biosciences, and a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, and Inari; she is a director at Johnson & Johnson. The authors declare no competing non-financial interests.